CHARLOTTE – Troutman Pepper Locke represented Telix Pharmaceuticals Limited (Telix) (ASX: TLX, NASDAQ: TLX), a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases, on its upsized US$600 million offering of convertible notes due 2031. For more information, see the press release.
The new bonds are expected to be listed on the Official List of the Singapore Exchange Securities Trading Limited and represent low-cost financing to Telix on a non-dilutive basis until any potential future conversions occur. The initial conversion price will be at a premium to Telix’s current share price.
The Troutman Pepper Locke team that advised Telix in the offering was led by Alex Yarbrough and included Tom Rose, Shona Smith, Tom Gray, Mark Goldsmith, Betty Segaar, Ted Edwards, Sam Baker, and Josh Eastwood.
Consistently recognized as a top-tier practice, Troutman Pepper Locke’s corporate attorneys regularly handle strategic deals for clients ranging from industry leading, Fortune 100 corporations to emerging companies. Core areas of service include mergers and acquisitions, corporate finance, corporate governance, securities laws compliance, capital markets transactions, and other significant domestic and cross-border transactions, as well as general corporate counseling.
Troutman Pepper Locke
Troutman Pepper Locke helps clients solve complex legal challenges and achieve their business goals in an ever-changing global economy. With more than 1,600 attorneys in 30+ offices, the firm serves clients in all major industry sectors, with particular depth in energy, financial services, health care and life sciences, insurance and reinsurance, private equity, and real estate. Learn more at troutman.com.